Novartis

Novartis recalls OTC drugs, temporarily closes U.S. plant

Monday, January 9, 2012 01:51 PM

Novartis is recalling several over-the-counter products such as Gas-X, Excedrin, NoDoz, and Bufferin due to inconsistent bottling, as well as broken gel caps and chipped pills.

More... »

Report: Clinical trials approved in Russia on course in third quarter

Monday, November 7, 2011 11:26 AM

The number of new studies approved in Russia during the third quarter of 2011 reached last year’s level, with the Ministry of Health and Social Development of the Russian Federation (MoH) approving 132 new clinical trials of all types, including local and bioequivalence studies, according to Synergy Research Group (SynRG), a Russia-based CRO. That’s only two trials below the number approved in the year-ago quarter.

More... »

CRO top executives in a game of ‘musical chairs’

Monday, November 7, 2011 08:02 AM

Five months after INC Research’s acquisition of Kendle International closed, executives from the now-combined CRO are landing jobs with competitors.  

More... »

Foundation Medicine, Johnson & Johnson collaborate in oncology research

Tuesday, October 25, 2011 01:10 PM

Foundation Medicine has reported a collaboration with Johnson & Johnson Pharmaceutical Research and Development. The collaboration is focused on using Foundation Medicine's comprehensive clinical cancer genomic test to identify potential biomarkers to support J&JPRD oncology clinical development programs. Financial details of the agreement were not disclosed.

More... »

Drug sponsors join research partnership to accelerate drug discovery

Thursday, September 29, 2011 01:21 PM

In a bid to save both time and money, some of the industry's biggest names are experimenting with new ways to pool early-stage research, effectively taking a leaf out of the "open-source" manual that gave the world Linux software, according to Reuters.

More... »

Tokai Pharmaceuticals raises $23 million in funding

Tuesday, September 20, 2011 01:45 PM

Tokai Pharmaceuticals, a biopharmaceutical company focused on developing new treatments for prostate cancer, has raised $23 million in a Series D3 financing. The proceeds will be used to support the ongoing clinical development of galeterone (TOK-001), the company's lead drug candidate, which has completed an initial proof-of-concept phase 1 clinical trial for the treatment of patients with castration resistant prostate cancer (CRPC). The financing round included both current investors, Novartis Venture Fund and Apple Tree Partners.

More... »

Novartis' canakinumab to potentially treat childhood arthritis

Monday, September 19, 2011 12:48 PM

Novartis has presented late-stage data showing that canakinumab, recently rejected by US regulators for gout, shows potential as a treatment for patients with the most serious form of childhood arthritis, according to PharmaTimes.

More... »

Roche CEO says diagnostics will maintain its lead in targeted drugs

Thursday, September 1, 2011 02:15 PM

Roche expects a new generation of drugs targeted at specific groups of patients to make up half its portfolio in 10 years, a shift that is pushing the boundaries of modern medicine, according to Reuters.

More... »

Novartis considers IPO in China

Wednesday, July 13, 2011 10:10 AM

Swiss drug maker Novartis is considering a possible initial public offering in China, joining a growing list of multinationals eyeing a listing on Shanghai's planned international board, two people with knowledge of the situation told Reuters.

More... »

Sangamo names Nichol executive vice president of R&D

Monday, July 11, 2011 12:48 PM

Sangamo BioSciences has named Geoffrey M. Nichol executive vice president, R&D. In this newly created position, Dr. Nichol will oversee all of the company's research and clinical development activities and operations.

More... »